- Home
- HQY vs EXEL Comparison
HQY vs EXEL Comparison
Compare HQY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQY
- EXEL
- Stock Information
- Founded
- HQY 2002
- EXEL 1994
- Country
- HQY United States
- EXEL United States
- Employees
- HQY N/A
- EXEL N/A
- Industry
- HQY Business Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQY Consumer Discretionary
- EXEL Health Care
- Exchange
- HQY Nasdaq
- EXEL Nasdaq
- Market Cap
- HQY 8.7B
- EXEL 9.8B
- IPO Year
- HQY 2014
- EXEL 2000
- Fundamental
- Price
- HQY $100.61
- EXEL $43.04
- Analyst Decision
- HQY Strong Buy
- EXEL Buy
- Analyst Count
- HQY 13
- EXEL 18
- Target Price
- HQY $111.77
- EXEL $38.76
- AVG Volume (30 Days)
- HQY 973.9K
- EXEL 3.9M
- Earning Date
- HQY 06-03-2025
- EXEL 05-13-2025
- Dividend Yield
- HQY N/A
- EXEL N/A
- EPS Growth
- HQY 70.31
- EXEL 237.58
- EPS
- HQY 1.09
- EXEL 2.20
- Revenue
- HQY $1,199,774,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- HQY $9.60
- EXEL $10.39
- Revenue Next Year
- HQY $10.04
- EXEL $10.74
- P/E Ratio
- HQY $92.30
- EXEL $19.53
- Revenue Growth
- HQY 20.03
- EXEL 24.49
- 52 Week Low
- HQY $65.01
- EXEL $20.40
- 52 Week High
- HQY $115.59
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- HQY 63.24
- EXEL 59.93
- Support Level
- HQY $97.00
- EXEL $42.21
- Resistance Level
- HQY $102.54
- EXEL $43.75
- Average True Range (ATR)
- HQY 2.79
- EXEL 1.60
- MACD
- HQY 0.23
- EXEL -0.09
- Stochastic Oscillator
- HQY 72.76
- EXEL 53.96
About HQY HealthEquity Inc.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.